PERVIChNYY SKLEROZIRUYuShchIY KhOLANGIT
- Authors: Vasil'ev Y.V1
-
Affiliations:
- Issue: No 6 (2013)
- Pages: 73-77
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/280568
- ID: 280568
Cite item
Open Access
Access granted
Abstract
The article discusses the problem of primary sclerosing cholangitis (PSC). Information on the pathogenesis, diagnosis, and treatment of PSC is presented. Particular attention is paid to the use of ursodeoxycholic acid (UDCA), hepatoprotector embeding in the membrane of hepatocytes that stabilizes the structure and protects liver cells from the damaging factors, inhibits the absorption of lipophilic bile acids in the intestine, induces the formation of bile enriched in bicarbonates (acid salts of carbonic acid), that results in increased passage of bile and stimulates the release of toxic bile acids in the intestine. Currently, UDCA may be considered as the primary drug in the treatment of PSC.
Full Text
References
- Angylo P, Maor-Kendler Y, Lindor KD. Smaiidukt hrimary sclerosing cholangitis: A long-term follow-up study. Hepatology 2002;35:1494-500.
- Buckles DS, Lindor KD, LaRusso NF, et al. In primary sclerusing cholangitis gallbladder polyps are frequently malignant. Am.J Gastroenterol 2002;97:1522-27.
- Bergouis A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 200;36:321-27.
- Brentnall TA, Haggitt RC, et al. Риск и естественное течение неоплазм ободочной кишки у больных первичным склерозирующим холангитом и язвенным колитом. Gastroenterology 1996;110:331-38.
- Burk K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523-26.
- Gilger MA, Gann ME, Opekun AR, et al. Efficacy of ursedeoxycholic acid in the treatment of primary sclerosing cholangitis in cgildren. J Peadiater Gastroenterol Nutr 2000;31:136-41.
- Harnois DM, Angulo P, Jorogensen RA, et al. High dose ursodeoxycholic acid as a thеrapy for patients with primary sderosing cholangitis. Am J Gastroenterol 2001;96:1558-62.
- Hempftirng W, Dilger R, Dtuers U. Systematic review: Ursodeoxycholic acid - Adverse effects and drug interactions. Aliment Pharmacol Ther 2003;18:963-72.
- Olsson R, Bjornsson E, Bfcrnfm L, еt al. Выделенные из желчных протоков бактерии при первичном склерозирующем холангите: исследование эксплантированной печени. J Hepatol 1998;28:426-32.
- Stiehl A, Rudolph G, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursedeoxy-cholic acid: Outcome after endoscopic treatment. J Hepatol 2002;36:151-56.
- Zein CO, Lindor, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepathology 2004;39:294-10.
- van Milligen der Wilt AWM, Kuiper H, Camoglio L, et al. Does ursodeoxycholic acid mediate immu-nodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis? Eur J Gastruenterol Hepatol 1999;11:129-36.
Supplementary files
